Home  >  News
Marketing + Font Resize -

Cipla gets US FDA marketing approval for generic Dacogen

Our Bureau, Mumbai
Monday, November 20, 2017, 12:30 Hrs  [IST]

Cipla Ltd, a global pharmaceutical company,  has received final approval for its Abbreviated New Drug Application (ANDA) for decitabine injection 50 mg single-use sterile vial from the United States Food and Drug Administration (FDA) to market generic version of Otsuka America Pharmaceutical Inc.’s Dacogen.

Cipla’s decitabine injection 50 mg/vial is AP-rated and is generic equivalent of Otsuka America Pharmaceutical Inc.’s, Dacogen. It is indicated for treatment of patients with myelodysplastic syndromes (MDS). The product is available for shipping immediately.

Dacogen and its generic equivalents had US sales of approximately $180 million for the 12-month period ending September 2017, as reported by IMS Health.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
CPhI-WW-Banners-150X60-120618-anim-v2
pharmalytica_150x60_2018
CPhI_MEA_Banner_150x60_2018
150X60px_biowavers
IPE_2018_Banner_150X60
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
CPhI_China_150x60-2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |